Platelet resistance to the anti-aggregating agents in the insulin resistant states

Current Diabetes Reviews

Volumn 2, Issue 4, 2006, Pages 409-430

  Anfossi, Giovanni ^a   Russo, Isabella ^a   Trovati, Mariella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Aspirin; Cardiovascular disease; Insulin; Insulin resistance; Nitric oxide; Obesity; Platelets; Thieno pyridines; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; CYCLIC GMP; CYCLIC NUCLEOTIDE; FIBRINOGEN RECEPTOR; INOSITOL TRISPHOSPHATE; INSULIN; ISOPROSTANE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE C; PICOTAMIDE; PROSTACYCLIN; PROSTANOID; STATIN; THROMBOXANE; TICLOPIDINE;

ALBUMINURIA; ALLERGY; ALTERNATIVE MEDICINE; BLEEDING; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL AGGREGATION; CELL PROLIFERATION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMOTAXIS; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CYTOSOLIC FRACTION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESISTANCE; DYSLIPIDEMIA; HALF LIFE TIME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATION; INSULIN RESISTANCE; INTRACELLULAR TRANSPORT; LIFESTYLE; LOW DRUG DOSE; MORTALITY; NEUTROPENIA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RETINA HEMORRHAGE; REVIEW; RISK FACTOR; SMOKING; THERAPY; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE ANOMALY; THROMBOGENESIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 33750955991     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/1573399810602040409     Document Type: Review

References (283)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 1709-16.
3. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006; 27: 96-106.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Faxtor Intervention Trial. Diabetes Care 1993; 16: 434-44.
5. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation 2003; 108: 1527-32.
6. Luscher TF, Creager MA. Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part II. Circulation 2003; 108:1655-61.
7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339; 229-34.
8. Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 2000; 102: 1014-9.
9. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
10. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867-72.
11. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005; 149: 54-60.
12. Wolk R, Berger P, Lennon RJ, Brilakis ES, Somers VK. Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 2003; 108: 2206-11.
13. Schwartz GG, Olsson AG, Szarek M, Sasiela W. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome. An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 2005; 28: 2508-13.
14. Alexander CM, Landsman PB, Teutsch SM, Haffner S: Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-4.
15. Ross R. Atherosclerosis: an inflammatory disease. N. Engl J Med 1999; 340: 115-26.
16. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diab Res Clin Pract 2000; 50: 1-16.
17. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-85.
18. Trovati M. Anfossi G. Mechanisms involved in platelet hyperactivation and platelet-endothelium interrelationships in diabetes mellitus. Curr Diab Rep 2002; 2: 316-22.
19. Mandal S, Sarode R, Dash S, Dash RJ. Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed non insulin-dependent diabetes mellitus. Am J Clin Pathol 1993; 100: 103-7.
20. Osende JI, Badimon JJ, Fuster V, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307-12.
21. Yazbek N, Bapat A, Kleiman N. Platelet abnormalities in diabetic mellitus. Coron Artery Dis 2003; 14: 365-71.
22. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res 1997: 29: 631-5.
23. Bartnik M, Malmberg K, Ryden L. Management of patients with type 2 diabetes after acute coronary syndromes. Diab Vase Dis Res 2005; 2: 144-54.
24. Kleiman NS, Lincoff AM, Kereiakes DJ et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin. Evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998; 97: 1912-20.
25. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vase Biol 2006; 26: 41-8.
26. Michelson AD. How platelets work: platelet function and dysfunction. J Thromb Thrombolysis 2003; 16: 7-12
27. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
28. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
29. Massberg S, Gawaz M, Grüner S et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003; 197: 41-9.
30. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
31. Aird WC. Endothelial cell heterogeneity and atherosclerosis. Curr Atheroscler Rep 2006; 8: 69-75.
32. Gawaz M, Langer H, May A. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-84.
33. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel role for endothelial intercellular adhesion molecule 1 (ICAM-1), αvβ3 integrin, and GPIbα. J Exp Med 1998; 187:329-39.
34. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-8.
35. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care 1994; 17: 818-23.
36. Jokl R, Klein RL, Lopes-Virella MF, Colwell JA. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care 1995; 18: 1150-55.
37. Andrè P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
38. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
39. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-8.
40. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc; Dis 1995; 38; 87-104.
41. Haslam RJ, Dickinson NT, Jang EK. Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost 1999; 82: 412-23.
42. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153-61.
43. Colman RW. Platelet cyclic adenosine monophosphate phosphodiesterases: targets for regulating platelet-related thrombosis. Semin Thromb Haemost 2004; 30: 451-60.
44. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671-81.
45. Maurice DH. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. Front Biosci 2005; 10: 1221-8.
46. Eigenthaler M, Nolte C, Halbrugge M, Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 1992; 205: 471-81.
47. Waldmann R, Nieberding M, Walter U. Vasodilator-stimulated protein phosphorylation in plateles is mediated by cAMP- and cGMP-dependent protein kinases. Eur J Biochem 1987; 167: 441-8.
48. Butt E, Abel K, Krieger M et al. cAMP and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol.Chem 1994; 269: 14509-17.
49. Reinhard M, Jarchau T, Walter U. Actin-based motility: stop and go with Ena/VASP proteins. Trends Biochem Sci 2001; 26: 243-9.
50. Harbeck B, Huttelmaier S, Schluter K, Jockusch BM, Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem 2000; 275: 30817-25.
51. Aszodi A, Pfeifer A, Ahmad M et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999; 18: 37-48.
52. Hauser W, Knobeloch KP, Eigenthaler M et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci USA 1999; 96: 8120-5.
53. Horstrup K. Jablonka B, Honig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994; 225: 21-7.
54. Fox JE, Berndt MC. Cyclic AMP-dependent phosphorylation of glycoprotein Ib inhibits collagen-induced polymerization of actin in platelets. J Biol Chem 1989; 264: 9520-6.
55. Wardell MR, Reynolds CC, Berndt MC, Wallace RW, Fox JE. Platelet glycoprotein Ib beta is phosphorylated on serine 166 by cyclic AMP-dependent protein kinase. J Biol Chem 1989; 264: 15656-61.
56. Siess W, Winegar DA, Lapetina EG. Rap 1 -B is phosphorylated by protein kinase A in intact human platelets. Biochem Biophys Res Commun 1990; 170: 944-50.
57. Torti M, Lapetina EG. Structure and function of rap proteins in human platelets. Thromb Haemost 1994; 71: 533-43.
58. Schultess J, Danielewski O, Smolenski AP. Rap1GAP2 is a new GTPase-activating protein of Rap1 expressed in human platelets. Blood 2005; 105: 3185-92.
59. Danielewski O, Schultess J, Smolenski AP. The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost 2005; 93: 319-25.
60. Haug LS, Jensen V, Hvalby O, Walaas SI, Ostvold AC. Phosphorylation of the inositol 1,4,5-trisphosphate receptor by cyclic nucleotide-dependent kinases in vitro and in rat cerebellar slices in situ. J Biol Chem 1999; 274: 7467-73.
61. Cavallini L, Coassin M, Borean A, Alexandre A. Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem 1996; 271: 5545-51.
62. IP4BP in highly purified human platelet membranes. Blood 2000; 95: 3412-22
63. 2+ uptake in human platelets by cAMP. Biochim Biophys Acta 1992; 1105: 29-39.
64. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochem Biophys Acta 1993; 1178: 153-75.
65. 3 receptor and cGMP kinase Ibeta. Nature 2000; 404: 197-201.
66. Ammendola A, Geiselhöringer A, Hofmann F, Schlossmann J. Molecular determinants of the interaction between the inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate (IRAG) and cGMP kinase Ibeta. J Biol Chem 2001; 276: 24153-9.
67. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem 2005; 280: 1-4.
68. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006; 86: 1-23.
69. Wang G-R, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci USA 1998; 95: 4888-93.
70. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-62.
71. Malinski T, Radomski MW, Taha Z, Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Common 1993; 194: 960-5
72. Michelson AD, Benoit SE, Furman MI et al. Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol 1996; 270: H1640-8.
73. Trovati M, Massucco P, Mattiello L et al. The insulin-induced increase of guanosine-3′,5′-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes 1996; 45: 768-70.
74. Trovati M, Anfossi G, Massucco P et al. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′,5′-cyclic monophosphate and adenosine-3′,5′-cyclic monophosphate. Diabetes 1997; 46: 742-9.
75. McDonagh PF, Hokama JY, Gale SC et al. Chronic expression of platelet adhesion proteins is associated with severe ischemic heart disease in type 2 diabetic patients: chronic platelet activation in diabetic heart patients. J Diab Compl 2003; 17: 269-78.
76. Matsuno H, Tokuda H, Ishisaki A, Zhou Y, Kitajima Y, Kozawa O. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J Clin Endocrinol Metab 2005; 90: 920-7.
77. Trovati M, Anfossi G. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia 1998; 41: 609-22.
78. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181-8.
79. Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005; 2: 16-23.
80. Anfossi G, Trovati M. Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy. Cardiovasc Hematol Agents Med Chem 2006; 4: 111-28.
81. Hajek AS, Joist JH, Baker RK, Jarett L, Daughaday WH. Demonstration and partial characterization of insulin receptors in human platelets. J Clin Invest 1979; 63: 1060-5.
82. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 1988; 157: 1190-6.
83. Trovati M, Anfossi G, Cavalot F et al. Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes 1986; 35: 818-25.
84. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 1988; 37: 780-6.
85. Trovati M, Anfossi G, Mularoni E, Massucco P, Bosia A, Emanuelli G. Insulin reduces platelet sensitivity to platelet activating factor in washed human platelets resuspended in a calcium-free medium. Diab Nutr Metab 1989; 2: 151-3.
86. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G: Physiological insulin concentrations reduce platelet sensitivity to adrenaline in vivo. In: Belfiore F, Molinatti GM, Reaven GM (Eds). Tissue specific metabolic alterations in diabetes. Frontiers in Diabetes, vol 10, Karger, Basel, 1990; 166-9.
87. Russo I, Massucco P, Mattiello L, Cavalot F, Anfossi G, Trovati M. Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thromb Res 2002; 107: 31-7.
88. Russo I, Massucco P, Mattiello L, Anfossi G, Trovati M Comparison between the effects of the rapid recombinant insulin analog Lispro (Lys B28, Pro B29) and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thromb Res 2003;109: 323-7.
89. Touyz RM, Schiffrin EL. Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients. J Hypertens 1994; 12: 1255-63.
90. Hiramatsu K, Nozaki H, Arimori A. Reduction of platelet aggregation induced by euglycaemic insulin clamp. Diabetologia 1987; 30: 310-3.
91. Westerbacka J, Yki-Jarvinen H, Turpeinen A et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002; 22: 167-72.
92. Mayfield R.K, Halushka PV, Wohltmann HJ et al. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes 1985; 34: 1127-33.
93. Trovati, M, Massucco P, Mattiello L, Mularoni E, Cavalot F, Anfossi G. Insulin increases guanosine-3′,5′-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect. Diabetes 1994; 43: 1015-9.
94. Fleming I, Schulz C, Fichtlscherer B, Kemp BE, Fisslthaler B, Busse R. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost 2003; 90: 863-71.
95. Udvardy G, Pflieger G, Rab K. Platelet insulin receptor determination in non-insulin-dependent diabetes mellitus. Experientia 1985; 41: 411-23.
96. Trovati M, Mularoni E, Burzacca S et al. Impaired insulin-induced platelet anti-aggregating effect in obesity and in obese NIDDM patients. Diabetes 1995; 44: 1318-22.
97. Ishibashi K, Kageyama S, Sakurai S et al. Inhibitory effects of insulin on intracellular calcium and aggregatory response of platelets are impaired in hypertensive subjects with insulin resistance. Hypertens Res 1997; 20: 225-31.
98. Anfossi G, Mularoni EM, Burzacca S et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998; 21: 121-6.
99. Anfossi G, Russo I, Massucco P et al. Impaired synthesis and action of anti-aggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest 2004; 34: 482-9.
100. Anfossi G, Mularoni E, Burzacca S et al. Impaired platelet sensitivity to the anti-aggregating effects of adenosine in obesity and obese non-insulin-dependent diabetes mellitus. In Belfiore F, Lorenzi M, Molinatti GM, Porta M Editors. Molecular and cell biology of type 2 diabetes and its complications, Frontiers in Diabetes vol. 14, Basel, Karger, 1998; 184-7.
101. Russo I, Doronzo G, Mattiello L, Trovati M, Anfossi G. Platelets from obese subjects are resistant to both cyclic GMP and cyclic AMP, the final mediators of plateletes anti-aggregation. Eur J Clin Invest 2005; 35 (suppl 2): 36-37.
102. Resnick LM. Cellular ions in hypertension, insulin resistance, obesity, and diabetes: a unifying theme. J Am Soc Nephrol 1992; 3: S78-85.
103. Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of "syndrome X". Am J Hypertens 1993; 6: 123S-34S.
104. Russo I, Traversa M, Bonomo, K et al. Platelet resistance to nitric oxide donors, prostacyclin and antiaggregating cyclic nucleotides is reverted by weight loss. Diabetologia 2005; 48 (Suppl 1): 706.
105. Russo I, Traversa M, Bonomo K et al. In obese subjects the platelet resistance to antiaggregating agents is reverted by weight loss. Eur J Clin Invest 2006; 36 (Suppl): 87.
106. Colwell JA. Aspirin for primary prevention of cardiovascular events in diabetes. Diabetes Care 2003; 26: 3349-50.
107. Colwell JA. Is aspirin effective in diabetic patients? Yes. J Thromb Haemost 2005; 3: 2612-4.
108. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268: 1292-300.
109. Hennekens CH, Knatterud GL, Pfeffer MA. Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. Diabetes Care 2004; 27: 2752-4.
110. Evangelista V, Totani L, Rotondo S et al. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 2005; 93: 8-16.
111. Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemostas 1997; 23: 349-56.
112. Rocca B, Secchiero P, Ciabattoni G et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-9.
113. Wu KK. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med 2003; 3: 107-12.
114. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-11.
115. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-60.
116. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366-72.
117. Patrono C, Coller B, Dalen JE et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119 (1 Suppl): 39S-63S.
118. Rinder CS, Student LA, Bonan JL, Rinder HM Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993; 82: 505-12.
119. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation, 1998; 97: 716-20.
120. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
121. Antithrombotic Tralists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
122. Eidelman RS, Herbert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10.
123. Landolfi R, Marchioli R, Kutti J et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-24.
124. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62
125. Harpaz D, Gottlieb S, Graff E, Boyko V, Kishon Y, Behar S. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Am J Med 1998;105: 494-9.
126. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 1997; 20: 1772-3.
127. American Diabetes Association. Antiplatelet agents. Diabetes Care 2006; 29: S19.
128. Cimminiello C, Milani M. Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events? Diabetologia 1996; 39: 1402-4.
129. Cimminiello C. Is aspirin effective in diabetic patients? No. J Thromb Haemost 2005; 3: 2615-6.
130. Di Minno G; Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-91.
131. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Järvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003; 27: 907-11.
132. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
133. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-72.
134. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Rognoni G, Nicolucci A. Aspirin Resistance in Diabetic Patients. Diabetes Care 2004; 27: 1246.
135. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991; 63. 587-93.
136. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31: 591-5.
137. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance J Thromb Thrombolys 2002; 13: 49-56.
138. Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 51-8.
139. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63-6.
140. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-3.
141. Di Minno G, Violi F. Aspirin resistance and diabetic angiopathy: back to the future. Thromb Res 2004; 113: 97-9.
142. Hennekens CH, Schror K, Wiesman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation 2004; 110: 1706-8.
143. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
144. Fateh-Moghadam S, Plockinger U, Cabeza N et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42: 99-103.
145. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 2006; 97: 567-70.
146. Mueller MR, Salat A, Stangl P et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
147. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. The PURSUIT Investigators: Platelet IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999; 83: 1147-51.
148. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
149. Jilma B, Fuchs I. Detecting aspirin resistance with the platelet function analyzer (PFA-100). Am J Cardiol 2001; 88: 1348-9.
150. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41; 961-5.
151. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? Am J Cardiol 2003; 41: 966-8.
152. McCabe DJ, Harrison P, Mackie IJ et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005; 16: 269-80.
153. Eikelboom JW, Hirsh J, Weitz H, Johnston M Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
154. De Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 2003; 1; 2048-50.
155. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004; 328: 477-9.
156. Michelson AD, Cattaneo M, Eikelboom JW et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-11
157. Schrör K, Weber AA, Hohlfels T. Aspirin "resistance". Blood Cells Mol Dis 2006; 36:171-6.
158. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the P1A2 polymorphism Am Heart J 2002; 143: 76-82.
159. Weiss EJ, Bray PF, Tayback PF et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
160. Bray PF, Weiss EJ, Tayback M, Goldschmidt-Clermont PJ. P1A1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease. Lancet, 1997; 349: 1100-1.
161. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet, 1997; 350: 1217-9.
162. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
163. Tschoepe D, Menart B, Ferber P et al. Genetic variation of the platelet- surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus. Diabetologia, 2003; 46: 984-9.
164. Watala C, Golanski J, Pluta J et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004; 113: 101-13.
165. Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005; 83: 148-58.
166. Howard PA. Aspirin resistance. Ann Pharmacother 2002; 36: 1620-4.
167. Madajka M; Korda M, White J, Malinski T. Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Thromb Res 2003; 110: 317-21.
168. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003; 14: 421-7.
169. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
170. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-54.
171. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-9.
172. Quinones MJ, Nicholas SB, Lyon CJ. Insulin resistance and the endothelium. Curr Diab Rep 2005; 5: 246-53.
173. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610-2.
174. Ferroni P, Basili S, Davi G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol 2003; 1: 157-69.
175. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005; 25: 1321-4.
176. Cipollone F, Ciabattoni G, Patrignani P et al. Oxidant stress and
177. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-7.
178. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-13.
179. Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004; 18: 1791-800.
180. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17: 2309-15.
181. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999; 274: 24441-4.
182. 2 receptor in vivo. Circulation 2000; 101: 2833-40.
183. Cracowski JL. Isoprostanes: an emerging role in vascular physiology and disease? Chem Phys Lipids 2004; 128: 75-83.
184. Pratico D, Smyth EM, Violi F, FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 1996; 271: 14916-24.
185. Davì G, Gresele P, Violi F et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
186. Keaney JF, Larson MG, Vasan RS et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23; 434-9.
187. Davì G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F. In vivo formation of 8-Epi-prostaglandin F2α is increased in hypercolesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3230-5.
188. Morrow JD, Frei B, Longmire AW et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-203.
189. Véricel E, Januel C, Carreras M, Moulin P, Lagarde M Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 2004; 53: 1046-51.
190. Desideri G, Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA 2003; 289: 1781-2.
191. Davì G, Guagnano MT, Ciabattoni G et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-14.
192. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 2003; 110: 281-6.
193. Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
194. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100; 1667-72.
195. TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990; 108: 1577-83.
196. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-8.
197. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
198. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26: 3333-41.
199. Mehilli J, Kastrati A, Schuhlen H et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110; 3627-35.
200. Tang WH, Lincoff AM. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: the triad revisited. Circulation 2004; 110: 3618-20.
201. Wyss CA, Roffi M. Platelet Inhibition in Percutaneous Coronary Interventions. Herz 2005; 30: 189-96.
202. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
203. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004; 109: 3064-7.
204. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45: 1157-64.
205. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647-54.
206. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2909-13.
207. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-8.
208. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93: 456-8.
209. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005; 115: 101-8.
210. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-51.
211. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
212. Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
213. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
214. Gurbel PA, Lau WC, Bliden KP, Tantry US. Clopidogrel resistance: implications for coronary stenting. Curr Pharm Des 2006; 12: 1261-9.
215. Lev EI, Patel RT, Maresh KJ et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
216. Tschoepe D, Driesch E, Schwippert B, Lampeter EF. Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. Diabetologia 1997; 40: 573-7.
217. Jinchuan Y, Zonggui W, Jinming C, Li L, Xiantao K. Upregulation of CD40 - CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 2004; 339: 85-90.
218. Ferreira IA, Mocking AI, Feijge MA et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26: 417-22.
219. Angiolllo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004; 16: 169-74.
220. Moshfegh K, Redondo M, Julmy F et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000; 36: 699-705.
221. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
222. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823-8.
223. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
224. Vinik AI, Vinik E. Prevention of the complications of diabetes. Am J Manag Care 2003; 9: S63-80.
225. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, for the CLASSICS Investigators. Double-blind study on the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 624-9.
226. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004; 164: 2106-10.
227. Klein L, Gheorghiade M. Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. Am J Med 2004; 116: 47S-63S.
228. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-5.
229. Neri Serneri GG Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845-52.
230. Berrettini M, De Cunto M, Parise P, Grasselli S, Nenci GG. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets. Eur J Clin Pharmacol 1990; 39: 495-500.
231. Cattaneo M, Tenconi PM, Lecchi A, Mannucci PM. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Thromb Res 1991; 62: 717-24.
232. Anfossi G, Parisi S, Russo I et al. Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. Thromb Res 1995; 77: 399-410.
233. 2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 2005; 112: 3001-8.
234. Alfranca A, Iñiguez MA, Fresno M, Redondo JM. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res 2006; 70: 446-56.
235. Giustina A, Perini P, Desenzani P, et al. Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 1998; 47: 423-30.
236. Fernandez de Arriba A, Cavalcanti F, Miralles A et al. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. Mol Pharmacol 1999; 55: 753-60
237. De La Cruz JP, Villalobos MA, Garcia PJ, Smith-Agreda JM, Sanchez de la Cuesta F. Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. Eur J Clin Pharmacol 1995; 47: 497-502.
238. Falco A, Salvati F, Vitacolonna E et al. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. Atherosclerosis 2005; 193: 329-35.
239. Colwell JA. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs 2004; 4: 87-106.
240. Puccetti L, Pasqui AL, Auteri A, Bruni F. Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 121-6.
241. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.
242. Hu G, Qiao Q, Tuomilehto J. The metabolic syndrome and cardiovascular risk. Curr Diab Rev 2005; 1: 137-43.
243. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100.
244. Rauramaa R, Vaisanen SB. Interaction of physical activity and diet: implications for haemostatic factors. Public Health Nutr 1999; 2: 383-90.
245. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
246. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003; 29: 6S44-52.
247. Charles MA, Morange P, Eschwege E, Andrè P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998; 21: 1967-72.
248. Gin H, Freyburger G, Boisseau M, Aubertin J. Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diab Res Clin Pract 1989; 6: 61-7.
249. Marfella R, Acampora R, Verrazzo G. et al. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care 1996; 19: 934-9.
250. Ishizuka T, Itaya S, Wada J et al. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998; 47: 1494-500.
251. Hishinuma T, Yamazaki T, Mizugaki M. Troglitazone has a reducing effect on thromboxane production. Prostaglandins Other Lipid Mediat 2000; 62: 135-43.
252. Marx N, Imhof A, Froehlich J et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-7.
253. de Dios ST, O'Brien RC, Little PJ. Clinical thiazolidinediones as PPARγ ligands with the potential for the prevention of cardiovascular disease in diabetes. Curr Diab Rev 2006; 2: 227-39.
254. Sidhu JS, Cowan D, Tooze JA, Kaski J-C. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am. Heart J 2004; 147: 25.
255. Pajunen P, Nieminen MS, Taskinen MR, Syvanne M. Quantitative comparison of angiographic characteristics of coronary artery disease in patients with noninsulin-dependent diabetes mellitus compared with matched nondiabetic control subjects. Am J Cardiol 1997; 80: 550-6.
256. Abizaid A, Kornowski R, Mintz GS et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-9.
257. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100: 123-8.
258. Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E. Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. Diabetologia 2000; 43: 632-41.
259. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937-43.
260. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293-300.
261. Koyama H, Nishizawa Y. Platelet in progression of atherosclerosis: a potential target in diabetic patients. Curr Diab Rev 2005; 1: 159-65.
262. Gazzaruso C, Solerte SB, De Amici E et al. Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 97: 236-9.
263. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diab Compl 2001; 15: 44-54.
264. Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diab Compl 2002; 16: 35-40.
265. Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003; 2: 2.
266. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-91.
267. Tschope D, Rosen P, Gries FA. Increase in the cytosolic concentration of calcium in platelets of diabetics type II. Thromb Res 1991; 62: 421-8.
268. Takaya H, Higashino H, Kotera F, Kobayashi Y. Intracellular magnesium of platelets in children with diabetes and obesity. Metabolism 2003; 52: 468-71.
269. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001; 280; H1480-9.
270. McDonagh PF, Hokama JY, Gale SC et al. Chronic expression of platelet adhesion proteins is associated with severe ischemic heart disease in type 2 diabetic patients: Chronic platelet activation in diabetic heart patients. J Diab Compl 2003; 17: 269-78.
271. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 2004; 53 (Suppl 3): S39-47.
272. Gaede P, Pedersen O. Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: what are we waiting for? Horm Metab Res 2005; 37 (Suppl 1): 76-82.
273. Elezi S, Kastrati A, Pache J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-73.
274. Labinaz M, Madan N, O'Shea JO et al. Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). Am J Cardiol 2002; 90: 585-90.
275. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217-25.
276. Kabbani SS, Watkins MW, Ashikaga T et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181-6.
277. Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists - the diabetic patient. Rev Cardiovasc Med 2002; 3: S20-7.
278. King SB, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 2000; 35: 1116-21.
279. Huber K. The role of glycoprotein IIb/IIIa-receptor antagonists in diabetics. J Thromb Thrombolysis 2003; 15: 99-103.
280. Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999; 100: 2477-84.
281. King SB, Mahmud E. Will blocking the platelet save the diabetic. Circulation 1999; 100: 2466-8.
282. McGill HC, McMahan CA, Herderick EE et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105: 2712-8.
283. Katzel LI, Sorkin KD, Colman E et al. Risk factors for exercise-induced silent myocardial ischemia in healthy volunteers. Am J Cardiol 1994; 74: 869-74.